Ollin Biosciences
Redefining What's Possible in Ophthalmology
Austin, United States · Founded 2023 · $430.0M raised
- Headquarters
- Austin, Texas
- Employees
- 11–50
- Founded
- 2023
- Business Model
- B2B
- Website
- ollin.bio
- Total Funding
- $430.0M
- Last Round
- $330.0M Venture RoundJun 2026
- Rounds
- 2
About
Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. Founded in 2023 and based in Austin, Texas, the company is advancing a pipeline of bispecific antibody programs including OLN324, a VEGF/Ang2 bispecific antibody in Phase 1b trials for wet AMD and diabetic macular edema, and OLN102 for thyroid eye disease.
Summary
Ollin Biosciences is a Biotech company based in Austin, United States, founded in 2023. It has raised $430.0M in total across 2 rounds, most recently a $330.0M Venture Round round in Jun 2026. Investors include ARCH Venture Partners, Mubadala Capital and Monograph Capital.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...